Once-a-Day Highly Active Antiretroviral Therapy: A Systematic Review

Ena, Javier; Pasquau, Francisco
May 2003
Clinical Infectious Diseases;5/1/2003, Vol. 36 Issue 9, p1186
Academic Journal
We analyzed the available evidence about the efficacy and tolerability of once-a-day highly active antiretroviral therapy (HAART), searching databases, conference proceedings, and journals. Two reviewers independently selected 6 uncontrolled and 2 randomized clinical trials of at least 24 weeks duration and with 800012F0F0articipant follow-up. Regimens included didanosine (ddI), emtricitabine (FTC), and efavirenz (EFV) (2 studies, 326 patients); ddI, lamivudine (3TC), and EFV (3 studies, 147 patients); ddI, 3TC, EFV, and adefovir dipivoxil (1 study, 11 patients); ddI, nevirapine, and EFV (1 study, 15 patients); and ddI, 3TC, indinavir, and ritonavir (1 study, 10 patients). Virological efficacy ranged between 70and 91 Preliminary randomized clinical trials showed that once-a-day regimens (ddI, 3TC, and EFV or ddI, FTC, and EFV) had a virological efficacy at least similar to that of conventional HAART. The overall CD4 cell increase was at least 114 lymphocytes/μL. Tolerability was good, with a low discontinuation rate.


Related Articles

  • Flow Diversion in Aneurysms Trial: the Design of the FIAT study. RAYMOND, J.; DARSAUT, T. E.; GUILBERT, F.; WEILL, A.; ROY, D. // Interventional Neuroradiology;jun2011, Vol. 17 Issue 2, p147 

    Intracranial aneurysms, particularly large and giant, fusiform or recurrent aneurysms are increasingly treated with flow diverters (FDs), a recently introduced and approved neurovascular device. While some rare cases may not be treated any other way, in most patients a more conventional,...

  • Amicus' Phase III with Amigal Short, Sweet; no Fabrazyme. Osborne, Randy // BioWorld Today;6/23/2009, Vol. 20 Issue 119, p1 

    The article reports on the Phase III trial using Amigal against Fabry disease to be conducted by Amicus Therapeutics Inc. It is noted that many expected that the company would not be able to push through with the third phase of the 60-patient, six-month trial. Under the trial, patients will be...

  • From the Editor. Peach, Richard K. // American Journal of Speech-Language Pathology;May2004, Vol. 13 Issue 2, p98 

    This article addresses some concerns on the utilization of randomized clinical trials (RCT) to determine the efficacy of clinical interventions in speech-language pathology. The author notes that in order to improve the overall credibility of the positive outcomes associated with many...

  • A Clinical Trial on the Treatment of Chronic Rhinosinusitis with Continuous Ultrasound. NAGHDI, SOOFIA; ANSARI, NOUREDDIN NAKHOSTIN; FARHADI, MOHAMMAD // Journal of Physical Therapy Science;2008, Vol. 20 Issue 4, p233 

    The article focuses on a clinical trial examining the effectiveness of continuous ultrasound on the treatment of patients with chronic maxillary and frontal sinusitis. It mentions that the study was conducted on thirty adults with chronic rhinosinusitis and therapeutic continuous ultrasound was...

  • Is Monotherapy Sufficient for Clinically Localized Prostate Cancer? McKiernan, James // AUANews;Sep2007, Vol. 12 Issue 9, p1 

    The article examines the effectiveness of monotherapy for clinically localized prostate cancer. The author claims that biochemical or prostate specific antigen (PSA) is the most commonly discussed end point for analyzing high risk prostate cancer. A randomized clinical trial of surgical...

  • EPO Treatment Is Safe for Indications Other than Hypertension in Renal Anemic Patients.  // Kidney;May/Jun99, Vol. 8 Issue 3, p131 

    Discusses the abstract of a study entitled `The safety of treatment with recombinant human erythropoietin in clinical use: A review of controlled studies,' by B. Sowade, O. Sowade, J. Mocks and others, published in the 1998 'International Journal of Molecular Medicine.'

  • Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials. Yusuf, Salim; Wittes, Janet; Probstfield, Jeffrey; Tyroler, Herman A. // JAMA: Journal of the American Medical Association;7/3/91, Vol. 266 Issue 1, p93 

    Discusses common drawbacks associated with analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Purpose of subgroup analysis; Comparison between proper and improper subgroups; Recommendations.

  • Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival. Broglio, Kristine R.; Berry, Donald A. // JNCI: Journal of the National Cancer Institute;12/2/2009, Vol. 101 Issue 23, p1642 

    Background: Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.

  • Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010. Califf, Robert M.; Zarin, Deborah A.; Kramer, Judith M.; Sherman, Rachel E.; Aberle, Laura H.; Tasneem, Asba // JAMA: Journal of the American Medical Association;5/2/2012, Vol. 307 Issue 17, p1838 

    The article examines the basic characteristics of interventional clinical trials in cardiovascular, mental health and oncology therapeutic areas contained in the ClinicalTrials.gov database of the U.S. The discrepancies between guidelines-based treatment recommendations and evidence from...

  • Strategy for randomised clinical trials in rare cancers. Say-Beng Tan; Dear, Keith B. G.; Bruzzi, Paolo; Machin, David // BMJ: British Medical Journal (International Edition);7/5/2003, Vol. 327 Issue 7405, p47 

    Discusses a strategy for randomised clinical trials in rare cancers. Need for randomised trials to establish that treatments are effective; Problems of small trials; Designing a new trial; Prior and posterior distribution.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics